Patents Represented by Attorney, Agent or Law Firm John P. Breen
-
Patent number: 6946475Abstract: The present invention is directed to compounds useful as cancer cell inhibitors, compositions containing such compounds and methods for inhibiting proliferation of electrically non-excitable cells.Type: GrantFiled: April 7, 2000Date of Patent: September 20, 2005Assignee: University of Virginia Patent FoundationInventors: Lloyd S. Gray, Timothy L. Macdonald, Doris Haverstick, Tiffany N. Heady
-
Patent number: 6759402Abstract: The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the formation of metabolites that are believed responsible for the toxicity associated with felbamate therapy.Type: GrantFiled: June 6, 2003Date of Patent: July 6, 2004Assignee: University of Virginia Patent FoundationInventors: Timothy L. Macdonald, Thomas A. Miller, Charles D. Thompson, Christine M. Dieckhaus
-
Patent number: 6649746Abstract: The invention provides a bioproduction of glutamine rich peptides. These peptides are used for rehydration and nutrition therapy in patients and for enhanced nutrition in animals. The peptides may be used as individual peptides or combined with other peptides in oligopeptides or proteins. Compositions of glutamine rich peptides and nucleic acid sequences for producing such peptides, as well as methods of production and use, are described.Type: GrantFiled: May 2, 2000Date of Patent: November 18, 2003Assignee: University of Virginia Patent FoundationInventors: Michael P. Timko, Richard L. Guerrant
-
Patent number: 6573060Abstract: Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.Type: GrantFiled: November 28, 2000Date of Patent: June 3, 2003Assignee: University of Virginia Patent FoundationInventors: Joel W. Hockensmith, Rohini Muthuswami
-
Patent number: 6537791Abstract: Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.Type: GrantFiled: November 28, 2000Date of Patent: March 25, 2003Assignee: University of Virginia Patent FoundationInventors: Joel W. Hockensmith, Rohini Muthuswami
-
Patent number: 6531306Abstract: Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.Type: GrantFiled: November 28, 2000Date of Patent: March 11, 2003Assignee: University of Virginia Patent FoundationInventors: Joel W. Hockensmith, Rohini Muthuswami
-
Patent number: 6399302Abstract: The present invention relates to oligonucleotide-based biosensors and a general method for their production and use. Specifically, the invention describes a novel signal-generating ligand complex comprising the combination of two or more aptamers linked together by a polymeric linker and further comprising a signaling system that provides a detectable signal upon binding of the signal-generating ligand complex to its target analyte.Type: GrantFiled: April 19, 2000Date of Patent: June 4, 2002Assignee: University of Virginia Patent FoundationInventors: Deborah A. Lannigan, Ian G. Macara
-
Patent number: 6329500Abstract: The present invention relates to a composition and method for inhibiting TGF-&bgr; activity. The composition comprises a TGF-&bgr; neutralizing peptide derived from &agr;2-macroglobulin that binds to TGF-&bgr; and inhibits TGF-&bgr; activity.Type: GrantFiled: May 13, 1999Date of Patent: December 11, 2001Assignee: University of Virginia Patent FoundationInventors: Donna J. Webb, Steven L. Gonias
-
Patent number: 6303299Abstract: The invention relates to a method for studying translation initiation and for identifying potential inhibitors of translation initiation by expressing proteins in the presence of misacylated suppressor tRNAs.Type: GrantFiled: May 13, 1998Date of Patent: October 16, 2001Assignee: University of Virginia Patent FoundationInventors: Sidney M. Hecht, Vladimir Karginov, Andrei V. Karginov
-
Patent number: 6258364Abstract: S19 mAb, deposited under Accession Number HB-12144 at the ATCC, binds to a carbohydrate epitope of a glycoprotein found distributed over the surface of sperm. The carbohydrate nature of the epitope, its distribution over the entire sperm surface, and the fact that it is epididymal/sperm specific and not naturally found in any of the tissues of the female reproductive tract, make the glycoprotein, SAGA-1, a desirable immunogen as the active agent for a contraceptive vaccine, as well as a test standard for monitoring antibody titer. The antibody provides a diagnostic for the presence of sperm, as well as a topical spermistatic.Type: GrantFiled: February 23, 1998Date of Patent: July 10, 2001Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Alan B. Diekman, V. Anne Westbrook-Case, Elizabeth J. Norton